Regulatory milestones

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) gained $0.37 to $10.96 last week after submitting an NDA to FDA for Zalviso sufentanil sublingual microtablet system to manage moderate to severe acute pain in a hospital setting. The company submitted the application under section 505(b)(2) of the Food, Drug and Cosmetic Act.